La cadena de opciones muestra datos clave de las opciones de acciones de Brenmiller Energy a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Brenmiller Energy..

Brenmiller Energy (NASDAQ:BNRG) Bolsa, Cadena de Opciones

Brenmiller Energy

Brenmiller Energy Ltd is a technology company that develops, produces, markets, and sells thermal energy storage. The technology of the company allows electrification and decarbonization of the industrial industry sector for integration with renewable energy sources and further reduction of carbon emissions.

WIIM

Centene shares are trading lower after the company withdrew its previous 2025 GAAP and adjusted diluted EPS guidance, including the underlying guidance elements.

News

Econ #s

Challenger Job Cuts (Jun) 47.999K, Down From 93.816K Prior

Alert signals reversal of early weakness in EQIX
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01203530/Screenshot-2025-07-01-at-4.32.31%E2%80%AFPM-1021x1024.png" alt="" class="wp-image-15203" /></figure>
Equinix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:28 AM on July 1st. a significant trading signal occurred for Equinix Inc. (EQIX) as it demonstrated a Power Inflow at a price of $786.99. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Equinix's stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Equinix's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for EQIX,<a href="https://benzinga.grsm.io/register174"> Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_July2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_July2025</a>
After Market Close UPDATE:
The price at the time of the Power Inflow was $786.99. The returns on the High price ($800.16) and Close price ($795.38) after the Power Inflow are respectively 1.7% and 1.1%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your appetite for risk.
Past performance is not indicative of future results

Equities

Technicals

Opinion

Signals

Trading Ideas

EQIX

Equinix Stock Up 1.7% After Key Trading Signal

Abeona Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $155 million on June 27, 2025.
Including net proceeds from the sale of the PRV, the Company reported that unaudited cash, cash equivalents, restricted cash and short-term investments&nbsp;as of June 30, 2025 were approximately $225 million.

ABEO

Abeona Therapeutics Nets $155M From Voucher Sale

Compass Point analyst Giuliano Bologna initiates coverage on Chime Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHYM#NASDAQ">CHYM</a>) with a Neutral rating and announces Price Target of $33.

Price Target

Initiation

Analyst Ratings

CHYM

Compass Point Initiates Coverage On Chime Financial with Neutral Rating, Announces Price Target of $33

Hewlett Packard Enterprise Completes Juniper Networks Acquisition, Doubling Networking Business To Deliver AI-Driven, Cloud-Native IT Solutions

ZenaTech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#NASDAQ">ZENA</a>) (FSE: 49Q) (BMV:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#BMV">ZENA</a>) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), and enterprise SaaS, has signed an offer to acquire a California-based civil engineering and land surveying firm with a well established history of operations. This marks ZenaTech's first proposed transaction in the US West Coast or Southwest region, creating a strategic entry point into California ─ a high-value market for drone-based precision agriculture due to a massive agriculture economy, crop diversity, labor and water challenges, and an openness to innovation.

BMV:ZENA

ZENA

ZenaTech Signs Offer To Acquire California-Based Civil Engineering And Land Surveying Firm For Undisclosed Terms

LITM

Snow Lake Energy JV Taps Single Drilling For 38,000m Campaign At Pine Ridge Uranium Project In Wyoming, Launch Set For July 21

UMH Properties Converts 188 Homes To Rentals In Q2, Boosts Occupancy To 94.4%, Reports 17% Rise In Home Sales Revenue

Contracts

REKR

Rekor Systems Extends Rekor Command Contract With Central Texas Regional Mobility Authority; $1.4M, 5-Year Agreement

<ul>
<li>Together, Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven add 30 satellite locations to enroll patients in BriaCell's pivotal Phase 3 study</li>
<li>BriaCell's Phase 3 study currently has 58 active clinical sites across 15 states, including Smilow Cancer Hospital, Los Angeles Cancer Network, University of Arizona, DHR Health Oncology Institute, Sylvester Comprehensive Cancer Center, Cancer Care Northwest, Hematology Oncology Associates of Fredericksburg, Northwestern University, Manhattan Hematology/Oncology Associates, New York Cancer &amp; Blood Specialists, and Texas Oncology-Baylor Charles A. Sammons Cancer Center</li>
</ul>
PHILADELPHIA and VANCOUVER, British Columbia, July 02, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>, BCTXW, BCTXZ))) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCT#TSX">BCT</a>) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce the addition of two key large cancer centers to its ongoing pivotal Phase 3 clinical study (ClinicalTrials.gov as <a href="https://www.globenewswire.com/Tracker?data=ELk5asFc4W_pTsyQ_74TVh24-Mzlu6753otmRhYbVjyY5sprIiAS-FCWSq69QBhEyHCx7x9gRWFsf1ZNn9YK9-cgazU5ZhbrMYHuLV8qXbsa_A-lrOs-_dwvbkvY30jW">NCT06072612</a>): Los Angeles Cancer Network and Smilow Cancer Hospital at New Haven. Each has 15 satellite locations. BriaCell anticipates completing patient enrollment in late 2025 or early 2026 and may report top line data as early as H1-2026.
BriaCell's pivotal Phase 3 clinical study is evaluating BriaCell's lead clinical candidate, Bria-IMT&#x2122;, plus immune check point inhibitor (CPI) versus physician's choice in advanced metastatic breast cancer (Bria-ABC).

BCTX

TSX:BCT

BriaCell Adds Two Key Large Cancer Centers To Ongoing Pivotal Phase 3 Clinical Study; Expects Completing Patient Enrollment In Late 2025 Or Early 2026 And May Report Top Line Data As Early As H1-2026

CME Group Reports Record Q2 ADV Of 30.2M Contracts, Driven By Interest Rates, Agriculture, Metals, And SOFR Futures Growth









Ask ChatGPT

JMP Securities analyst Nicholas Jones maintains Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) with a Market Outperform and raises the price target from $275 to $440.

CVNA

JMP Securities Maintains Market Outperform on Carvana, Raises Price Target to $440

BWMN

Bowman Enters Agreement To Acquire e3i Engineers, Financed Through Combination Of Cash, Seller Notes and Convertible Note; Bowman Anticipates Deal Will Initially Operate At Annualized Net Service Billing Run Rate ~$2M

DEFT

DeFi Technologies' Subsidiary Valour Launches Eight New SEK-Denominated ETPs On Sweden's Spotlight Stock Market

Canaccord Genuity analyst Katie Lachapelle upgrades Energy Fuels (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UUUU#AMEX">UUUU</a>) from Speculative Buy to Buy and raises the price target from C$9.5 to C$9.75.

Upgrades

UUUU

Canaccord Genuity Upgrades Energy Fuels to Buy, Raises Price Target to C$9.75

JMP Securities analyst Nicholas Jones maintains ACV Auctions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACVA#NYSE">ACVA</a>) with a Market Outperform and raises the price target from $18 to $20.

ACVA

JMP Securities Maintains Market Outperform on ACV Auctions, Raises Price Target to $20

Organon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>), a global healthcare company with a focus on women's health, today announced that the Phase 2 ELENA proof-of-concept study evaluating the investigational candidate OG-6219 in endometriosis-related pain did not meet its primary efficacy endpoint. OG-6219 is an oral 17β-hydroxysteroid dehydrogenase type 1 (HSD17B1) inhibitor, which Organon acquired through its acquisition of Forendo Pharma in 2021. In the study, OG-6219 did not demonstrate improvement in moderate-to-severe endometriosis-related overall pelvic pain compared to placebo. Based on these results, the company plans to discontinue the OG-6219 clinical development program.
"While these study results are disappointing, Organon remains committed to our long-term vision to create a better and healthier every day for all women including those living with endometriosis," said Juan Camilo Arjona Ferreira, M.D., Head of Research &amp; Development and Chief Medical Officer at Organon. "We are grateful to all the patients, caregivers, and investigators for their participation in and support of this study."
The randomized, double-blind, placebo-controlled, parallel-group, global multi-center Phase 2a/b study (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05560646&amp;esheet=54284964&amp;newsitemid=20250702870387&amp;lan=en-US&amp;anchor=NCT05560646&amp;index=1&amp;md5=aeb9426ea542f0de34677cf468d5fbed">NCT05560646</a>) aimed to evaluate the efficacy, safety, and tolerability of three dose levels of OG-6219 in pre-menopausal women 18 to 49 years of age who have been surgically diagnosed with endometriosis with moderate-to-severe endometriosis-related pain. Eligible patients were randomized to receive one of three doses of OG-6219 or placebo orally twice a day. The primary efficacy endpoint was the change from the baseline cycle (placebo run-in cycle) to the last planned treatment cycle (third month of treatment exposure), in the mean endometriosis-related overall pelvic pain score (measured using an eleven-point numerical rating scale).

Biotech

Health Care

General

Organon's Phase 2 Elena Proof-of-concept Study Of OG-6219 In Endometriosis-related Pain Did Not Meet Its Primary Efficacy Endpoint, Discontinues The OG-6219 Clinical Development Program

VCIG

VCI Global Announces Launch Of Qsecore Encryption Platform

KSX Search Xcelerator's 9th Acquisition
Asset-light industrial equipment services business with recurring revenues and strong growth prospects
Purchase price of $22.4 million
Trailing 12-month unaudited revenue of $16.0 million
Trailing 12-month unaudited adjusted EBITDA of $4.2 million
CHICAGO, IL / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / July 2, 2025 / Kingsway Financial Services Inc. ("Kingsway" or the "Company"), the only publicly-traded US company employing the Search Fund model to acquire and build great businesses, today announced the acquisition of Roundhouse Electric &amp; Equipment Co., Inc. ("Roundhouse"), a leading provider of industrial-scale electric motor maintenance, repair, testing, and sales solutions based in Odessa, Texas, for a purchase price of $22.4 million, plus transaction expenses and a working capital adjustment.
The transaction closed on July 1, 2025, and was funded with $10.4 million in cash on hand and $11.0 million from a senior credit facility. As part of the transaction, the selling shareholders are maintaining an economic interest in the go-forward entity, reflecting their continued belief in the company's long-term prospects and their alignment with Kingsway's growth vision.

Kingsway Acquires Roundhouse Electric & Equipment For $22.4M, Plus Transaction Expenses And Working Capital Adjustment

Press Releases

VIEWPOINT: Brenmiller Energy's CBO on Why Thermal Energy Storage is Critical to Nuclear's Second Act

Brenmiller Energy's Nears Its Transformative TES Market Moment ($BNRG)

Brenmiller Energy CEO Provides Update On Milestones Powering Progress

VIEWPOINT: Big Tech Just Saved Nuclear -Now It Needs Thermal Storage to Work

Brenmiller Energy Ltd. Announces Expected Implementation of 5-for-1 Reverse Share Split

Brenmiller Energy Comments on Reverse Share Split Ahead of Expected Near-Term Milestones

Brenmiller Energy Is Now The Only Public TES Stock Standing-Get It While It's Still Under the Radar

Brenmiller Energy Appoints Boaz Toshav to Serve as an Independent Director on the Board

Brenmiller Energy: The $2.50 Thermal Energy Storage Stock Powering a Critical Energy Shift-And Still Flying Under the Radar

Brenmiller Energy Signs a Memorandum of Understanding to Advance Thermal Energy Storage Solutions in Japan with a Major Japanese Corporation

BNRG

HLGN

Comments

Brenmiller Energy

Brenmiller Energy (BNRG) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL